Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lomustine

lomustine

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lomustine

9 trials tracked of lomustine: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 198 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 7 Other / NA 1
  1. Phase 3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed · 198 cited
  2. Phase 2 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Completed
  3. Phase 2 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Completed
  4. Phase 2 Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) Completed
  5. Phase 2 Lerapolturev in Recurrent Malignant Glioma Completed
  6. Phase 2 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Completed
Show 3 more trials
  1. Phase 2 A Study in Recurrent Glioblastoma (GB) Completed
  2. Phase 2 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Completed
  3. N/A Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
Pediatrics Phase III
Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients Trial Shows Reduced Radiation May Help Children With Medulloblastoma
This randomized phase 3 trial evaluated reduced-dose craniospinal radiation (18.00 Gy) and a smaller volume boost in children aged 3 to 7 wi…
A large clinical trial looked at whether reducing radiation doses for children with medulloblastoma can maintain safety and effectiveness.
CT.gov Jun 10, 2026
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Oncology Meta-analysis
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
May 1, 2026
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026